Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Molecular Immunoassay Diagnoses Melioidosis

By Labmedica International staff writers
Posted on 18 Feb 2013
Image: Burkholderia pseudomallei (Photo courtesy US Centers of Disease Control.
Image: Burkholderia pseudomallei (Photo courtesy US Centers of Disease Control.
Melioidosis is caused by the Gram-negative bacterium Burkholderia pseudomallei for which the standard test growing it on microbiological culture media, which requires at least 3 to 4 days to obtain a result, hindering successful treatment of acute disease.

Where the seroprevalence of antibodies to B. pseudomallei is relatively low, serology is a potentially advantageous addition to culture in the diagnosis of melioidosis and serology would be very effective in diagnosing travelers and military personnel returning from endemic tropical areas.

Scientists at James Cook University (Douglas, Australia) developed an enzyme-linked immunosorbent assay (ELISA) and a quantitative immunopolymerase chain reaction (PCR) assay capable of detecting melioidosis-specific antibodies. They demonstrated their validity with indirect haemagglutination assay (IHA)-negative sera from patients with melioidosis. A total of 10 serum samples from three IHA-positive and three IHA-negative melioidosis patients were tested along with sera from six healthy controls.

To verify the assays, the scientists used various techniques including immunoblotting, indirect peroxidase-conjugated protein G ELISA, and indirect terminus utilization substance (Tus) - DNA replication terminator sites (Ter)-lock immuno-PCR. Both the latter systems Both systems were based on the detection of immunoglobulin G (IgG) by protein G conjugated to a signal generation system consisting of either the enzymatic activity of peroxidase or a quantitative PCR (qIPCR) read-out in the case of Tus and the TT-lock-T DNA probe. All patient sera, including that collected at presentation and in subsequent follow-up collections, reacted against the B. pseudomallei antigenic fraction in both the G-peroxidase ELISA and TT-lock qIPCR format. Individual negative control sera from six healthy controls did not react against the B. pseudomallei antigenic fraction in either assay.


The authors concluded that although the indirect TT-lock qIPCR system is slightly slower than the ELISA format, it requires the least amount of serum and would be advantageous when multiple testing is required for the confirmation of disease. The ability to detect antibodies in patient sera that were persistently IHA negative is very promising, indicating that both immunoassay formats will be ideal for the rapid and reliable diagnosis of melioidosis in patients in nonendemic regions. The study was published in the February 2013 edition of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

James Cook University



ADVANCED INSTRUMENTS
VIRCELL
DiagCor Bioscience
comments powered by Disqus
Life Technologies

Channels

Genetic Tests

view channel

Next Generation Sequencing Reveals Genetic Basis for Congenital Cataracts

Applying the latest high-throughput, next-generation DNA sequencing technology has enabled researchers in the United Kingdom to diagnose children with rare diseases that are characterized by the formation of congenital cataracts. Diagnosing which of the more than 100 diseases that cause between 20,000 and 40,000 cases... Read more

Pathology

view channel
Image: Histopathology of increased endomysial connective tissue from a patient with Duchenne Muscular Dystrophy. Necrotic fibers arrowed (Photo courtesy of Washington University in St. Louis).

New Partnership Designed to Automate Dystrophin Measurement

A developer of innovative ribonucleic acid (RNA)-based therapeutics, Sarepta Therapeutics, Inc. ( Cambridge, MA, USA), and a leading tissue-based companion diagnostics firm, Flagship Biosciences LLC (Boulder,... Read more

Lab Tech.

view channel
Image: A technical breakthrough for DNA imaging has been achieved that should quicken diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various pre-natal conditions (Photo courtesy of McGill University and Génome Québec Innovation Center).

Breakthrough DNA Analysis Technology to Hasten Problem Diagnosis

Researchers have achieved a technical breakthrough that should result in speedier diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various... Read more

Industry News

view channel

Most IVD Sector Companies Look Outside the EU and USA for Growth

Kalorama Information (New York City, NY, USA) has now published the 9th edition of its biennial market research report “Worldwide Market for In Vitro Diagnostics,” revealing estimates from its survey of the in vitro diagnostics (IVD) industry – presenting the trends, technologies, customer needs, and major suppliers with... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.